Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alexion/P&G Pexelizumab Failed Phase III Could Compromise Development Partnership

This article was originally published in The Pink Sheet Daily

Executive Summary

The APEX-AMI study of pexelizumab in patients with acute myocardial infarction failed to meet its endpoint of reduction in mortality.

You may also be interested in...



Alexion Announces Settlement On Eculizumab Patent; $66.4 Million In Sales For Soliris

The single-product company will pay Oklahoma Medical Research Foundation $10 million, ending a patent-infringement suit.

Alexion Announces Settlement On Eculizumab Patent; $66.4 Million In Sales For Soliris

The single-product company will pay Oklahoma Medical Research Foundation $10 million, ending a patent-infringement suit.

Alexion Will Submit Soliris BLA By Year-End

The company will await final data from the 12-month SHEPHERD study to submit eculizumab for paroxysmal noctural hemoglobinuria.

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel